Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine and Methylphenidate for Methamphetamine Use Disorder
NCT04178993Phase 1Completed
- Start
- Sep 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of duloxetine and methylphenidate hydrochloride extended-release chewable tablet in methamphetamine use disorder (MUD) (2 arms). Primary endpoints: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance, Reinforcing Effects of Methamphetamine Following Methylphenidate (20 mg) Maintenance and 2 more. Started Sep 2019; status: completed.
02
Drugs
duloxetinemethylphenidate hydrochloride extended-release chewable tablet
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT04178993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04178993.